骨保护素在糖尿病大鼠主动脉粥样斑块和血管钙化中的表达

doi:10.3969/j.issn.1673-8640.2017.04.020

摘要/Abstract

摘要：

目的探讨骨保护素（OPG）在糖尿病大鼠主动脉粥样斑块和血管钙化中的表达水平以及吡格列酮对其的干预作用。方法选取健康雄性SD大鼠42只,随机分为6组[对照组（A组）、糖尿病组（B组）、主动脉粥样斑块和血管钙化组（C组）、糖尿病+主动脉粥样斑块和血管钙化组（D组）、主动脉粥样斑块和血管钙化+吡格列酮组（E组）、糖尿病+主动脉粥样斑块和血管钙化+吡格列酮组（F组）],每组7只。各组大鼠于实验第30天取血并分离血清,检测高敏C反应蛋白（hs-CRP）、空腹血糖（FPG）、HbA_1c和OPG;同时进行胸主动脉钙沉积含量和碱性磷酸酶（ALP）活性测定。结果糖尿病大鼠造模成功率为100%。与A组比较,C组、D组和E组胸主动脉钙沉积含量、ALP活性及血清OPG、hs-CRP水平明显升高（P<0.05）;F组胸主动脉钙沉积含量及ALP活性明显升高（P<0.05）,而血清hs-CRP、OPG水平差异无统计学意义（P>0.05）。C组胸主动脉钙沉积含量、ALP活性及血清OPG水平与E组比较,差异均有统计学意义（P<0.05）。D组胸主动脉钙沉积含量、ALP活性及血清hs-CRP、FPG、HbA_1c、OPG水平与E组和F组比较,差异均有统计学意义（P<0.05）。F组胸主动脉钙沉积含量和血清OPG水平明显低于E组（P<0.05）。OPG与血管钙含量、ALP、hs-CRP、FPG呈正相关（r值分别为0.654、0.218、0.539、0.711,P<0.05或P<0.01）。结论吡格列酮可降低大鼠主动脉粥样斑块和血管钙化的形成,其机制可能与调控OPG的表达,抑制炎症反应,降低钙盐沉积有关。

关键词: 骨保护素, 动脉粥样硬化, 糖尿病, 血管钙化

Abstract:

Objective To investigate the expression of osteoprotegerin（OPG） on aortic atherosclerotic plaques and vascular calcification of diabetes mellitus rats and the interference of pioglitazone. Methods A total of healthy male SD rats were enrolled and classified into 6 groups randomly,and there were 7 rats in each group,including control group （group A）,diabetes mellitus group（group B）,aortic atherosclerotic plaque and vessel calcification group（group C）,diabetes mellitus+aortic atherosclerotic plaque and vessel calcification group（group D）,aortic atherosclerotic plaque and vessel calcification+pioglitazone group（group E） ,diabetes mellitus+aortic atherosclerotic plaque and vessel calcification+pioglitazone group（group F）. Blood was extracted from rats on the 30th day for the determinations of high-sensitivity C-reactive protein（hs-CRP）,fasting plasma glucose（FPG）,glycated hemoglobin A _1c（HbA_1c）and OPG. Calcium deposits in thoracic aorta and alkaline phosphatase（ALP） activity were determined. Results The success rate of diabetes mellitus rat modeling was 100%. Compared with group A,the levels of calcium deposits in thoracic aorta,ALP activities,OPG and hs-CRP in group C,D and E increased（P<0.05）. The levels of calcium deposits in thoracic aorta and ALP activities increased（P<0.05）,and there was no statistical significance for hs-CRP and OPG in group F（P>0.05）. The levels of calcium deposits in thoracic aorta,ALP activities and OPG had statistical significance between group C and E（P<0.05）. The levels of ALP activities,hs-CRP,FPG,HbA_1c and OPG between group D and F were statistically significant（P<0.05）. The levels of calcium deposits in thoracic aorta and OPG in group F were lower than those in group E（P<0.05）. OPG was positively related with the levels of calcium deposits in thoracic aorta,ALP activities and hs-CRP and FPG（r=0.654,0.218,0.539 and 0.711,P<0.05 or P<0.01）. Conclusions Pioglitazone can reduce the formation of aortic atherosclerotic plaques and vessel calcification,and the mechanism might be related to the regulation of OPG,the inhibition of inflammatory reaction and the decreasing of calcium salt deposition.

Key words: Osteoprotegerin, Atherosclerosis, Diabetes mellitus, Vessel calcification

中图分类号:

R446.1

孙业富, 陈桂明, 夏爱萍, 张志锋. 骨保护素在糖尿病大鼠主动脉粥样斑块和血管钙化中的表达[J]. 检验医学, 2017, 32(4): 333-337.

SUN Yefu, CHEN Guiming, XIA Aiping, ZHANG Zhifeng. Osteoprotegerin expression on aortic atherosclerotic plaques and vessel calcification of diabetes mellitus rats[J]. Laboratory Medicine, 2017, 32(4): 333-337.

图/表 1

参考文献 27

[1]	Task Force on Diabetes,Pre-diabetes,and Cardiovascular Diseases of the European Society of Cardiology,European Association for the Study of Diabetes,RYDéN L,et al.ESC guidelines on diabetes,pre-diabetes,and cardiovascular diseases developed in collaboration with the EASD-summary[J]. Diab Vasc Dis Res,2014,11(3):133-173.
[2]	周小莉,林尤斌,王斐,等.2型糖尿病患者并发动脉粥样硬化的影响因素分析[J].实用心脑肺血管病杂志,2016,24(2):155-157.
[3]	WILDING J P.PPAR agonists for the treatment of cardiovascular disease in patients with diabetes[J].Diabetes Obes Metab,2012,14(11):973-982.
[4]	陈桂明,孙业富,夏爱萍,等.2型糖尿病并发骨质疏松病变患者血清OPG及C-反应蛋白与尿微量清蛋白/肌酐比值的关系[J].国际检验医学杂志,2016,37(1):87-89.
[5]	MASER R E,LENHARD M J,SNEIDER M B,et al.Osteoprotegerin is a better serum biomarker of coronary artery calcification than osteocalcin in type 2 diabetes[J]. Endocr Pract,2015,21(1):14-22.
[6]	王园园,龙民慧,邹民吉,等.大鼠动脉粥样硬化动物模型的建立和评价[J]. 中国实验动物学报,2008,16(6):421-423.
[7]	周永刚,蓝晓红,李祥,等.动脉粥样硬化大鼠实验模型的建立与评价[J]. 解放军药学学报,2011,27(5):399-403.
[8]	李同达,曹洪欣,徐慧,等.冠状动脉粥样硬化大鼠实验动物模型的改进与评价[J]. 中国实验动物学报,2013,21(6):32-36.
[9]	王竹,杨月欣,向雪松,等.实验大鼠血糖正常范围的估算[J]. 卫生研究,2010,39(2):133-137.
[10]	中华人民共和国科学技术部. 关于善待实验动物的指导性意见[Z].2006-09-30.
[11]	GONG Z,XING S,ZHENG F,et al.Increased expression of macrophage migration inhibitory factor in aorta of patients with coronary atherosclerosis[J]. J Cardiovasc Surg (Torino),2015,56(4):631-637.
[12]	皮银珍,杨腾舜,莫娟,等.糖尿病慢性并发症患者护骨素水平分布及调脂干预研究[J]. 湖南师范大学学报(医学版),2014,11(4):18-20.
[13]	SAITO I,KOKUBO Y,YAMAGISHI K,et al.Diabetes and the risk of coronary heart disease in the general Japanese population: the Japan Public Health Center-based prospective (JPHC) study[J].Atherosclerosis,2011,216(1):187-191.
[14]	SUGAWARA A,URUNO A,KUDO M,et al.Effects of PPARγ on hypertension,atherosclerosis,and chronic kidney disease[J]. Endocr J,2010,57(10):847-852.
[15]	ARMSTRONG Z B,BOUGHNER D R,DRANGOVA M A,et al.Angiotensin Ⅱ type 1 receptor blocker inhibits arterial calcification in a pre-clinical model[J]. Cardiovasc Res,2011,90(1):165-170.
[16]	KARWOWSKI W,NAUMNIK B,SZCZEPA SKI M,et al . The mechanism of vascular calci-fication-a systematic review[J]. Med Sci Monit,2012,18(1):RA1-RA11.
[17]	SIMONET W S,LACEY D L,DUNSTAN C R,et al.Osteoprotegerin:a novel secreted protein involved in the regulation of bone density[J]. Cell,1997,89(2):309-319.
[18]	杨立顺,袁海生,沈兴娅,等. 绝经后骨质疏松症相关骨代谢指标的分析[J]. 检验医学,2013,28(8):685-689.
[19]	PéREZ DE CIRIZA C,LAWRIE A,VARO N. Osteoprotegerin in Cardiometabolic Disorders[J]. Int J Endocrinol,2015,2015:564934.
[20]	BUMDELGER B,KOKUBO H,KAMATA R,et al.Osteoprotegerin prevents development of abdominal aortic aneurysms[J]. PLoS One,2016,11(1):e0147088.
[21]	MAKAROVI S,MAKAROVI Z,STEINER R,et al.Osteoprotegerin and vascular calcification: clinical and prognostic relevance[J]. Coll Antropol,2015,39(2):461-468.
[22]	WANG F,LERMAN A,HERRMANN J.Dysfunction of the ubiquitin-proteasome system in atherosclerotic cardiovascular disease[J]. Am J Cardiovasc Dis,2015,5(1): 83-100.
[23]	MASER R E,LENHARD M J,SNEIDER M B,et al.Osteoprotegerin is a better serum biomarker of coronary artery calcification than osteocalcin in type 2 diabetes[J]. Endocr Pract,2015,21(1):14-22.
[24]	OZKOK A,CALISKAN Y,SAKACI T,et al.Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients[J]. Clin J Am Soc Nephrol,2012,7(6):965-973.
[25]	BJERRE M.Osteoprotegerin(OPG) as a biomarker for diabetic cardiovascular complica-tions[J].Springerplus,2013,2:658.
[26]	WANG S T,ZHANG C Y,ZHANG C M,et al.The plasma osteoprotegerin level and osteo-protegerin expression in renal biopsy tissue are increased in type 2 diabetes with nephrop-athy[J]. Exp Clin Endocrinol Diabetes,2015,123(2):106-111.
[27]	KIM J Y,PARK Y J,KIM K J,et al.Osteoprotegerin causes apoptosis of endothelial progenitor cells by induction of oxidative stress[J].Arthritis Rheum,2013,65(8):2172-2182.

组别	例数	hs-CRP（mmol/L）	FPG（mmol/L）	HbA_1c（%）	钙（μmol/L）	ALP（IU/L）	OPG （ng/L）
A组	7	25.39±12.21	5.05±1.14	4.17±0.85	18.15±1.47	19.03±1.46	2.17±0.36
B组	7	32.25±9.32	18.63±4.55^*	24.89±4.52^*	22.25±4.30	28.25±5.34	3.42±0.39
C组	7	188.67±65.16^*	8.42±2.19	6.79±1.13	58.25±16.17^*	79.25±8.22^*	4.79±0.65^*
D组	5	219.31±80.95^*	22.75±5.16^*	26.62±6.29^*	76.11±19.87^*	101.25±7.06^*	5.62±0.99^*
E组	7	36.52±19.26^*#△	6.25±1.94^△	6.04±1.17^△	33.53±9.39^*#△	83.11±9.52^*#△	3.94±0.55^*#△
F组	6	32.77±16.43^△	6.78±2.77^*△	6.73±1.39^*△	27.31±6.55^*△▲	72.44±5.38^*△	2.79±0.41^△▲

组别	例数	hs-CRP（mmol/L）	FPG（mmol/L）	HbA_1c（%）	钙（μmol/L）	ALP（IU/L）	OPG （ng/L）
A组	7	25.39±12.21	5.05±1.14	4.17±0.85	18.15±1.47	19.03±1.46	2.17±0.36
B组	7	32.25±9.32	18.63±4.55^*	24.89±4.52^*	22.25±4.30	28.25±5.34	3.42±0.39
C组	7	188.67±65.16^*	8.42±2.19	6.79±1.13	58.25±16.17^*	79.25±8.22^*	4.79±0.65^*
D组	5	219.31±80.95^*	22.75±5.16^*	26.62±6.29^*	76.11±19.87^*	101.25±7.06^*	5.62±0.99^*
E组	7	36.52±19.26^*#△	6.25±1.94^△	6.04±1.17^△	33.53±9.39^*#△	83.11±9.52^*#△	3.94±0.55^*#△
F组	6	32.77±16.43^△	6.78±2.77^*△	6.73±1.39^*△	27.31±6.55^*△▲	72.44±5.38^*△	2.79±0.41^△▲